Patients with systemic lupus erythematosus (SLE) are at increased risk of premature atherosclerosis, mediated by endothelial dysfunction and increased arterial stiffness [1] . The latter, most commonly assessed using carotid-femoral pulse wave velocity, is increased in patients with SLE and is associated with cardiovascular risk factors [1] . Recently, a more sensitive measure of arterial stiffness (effective arterial elastance; Ea), and ventricular-arterial coupling (ratio of arterial and end-systolic ventricular elastance; Ea/Ees) demonstrated incremental prognostic value in patients with chronic heart failure [2]. We aimed to assess the potential of Ea and Ea/Ees as novel biomarkers of cardiovascular risk in SLE women without ischemic heart disease.
To the Editor:
Patients with systemic lupus erythematosus (SLE) are at increased risk of premature atherosclerosis, mediated by endothelial dysfunction and increased arterial stiffness [1] . The latter, most commonly assessed using carotid-femoral pulse wave velocity, is increased in patients with SLE and is associated with cardiovascular risk factors [1] . Recently, a more sensitive measure of arterial stiffness (effective arterial elastance; Ea), and ventricular-arterial coupling (ratio of arterial and end-systolic ventricular elastance; Ea/Ees) demonstrated incremental prognostic value in patients with chronic heart failure [2] . We aimed to assess the potential of Ea and Ea/Ees as novel biomarkers of cardiovascular risk in SLE women without ischemic heart disease.
Women who satisfied the revised American College of Rheumatology classification criteria for SLE were prospectively recruited from the rheumatology clinics, as described previously [3] . Patients with recent active flares, ischemic heart disease (all patients underwent nuclear stress perfusion imaging as part of the study), cardiomyopathies (including myocarditis) and valvular heart disease of ≥ moderate severity were excluded. Cardiovascular risk was defined as history of hypertension, hyperlipidemia, diabetes mellitus, current tobacco use, cerebrovascular events, family history of coronary artery disease and secondary anti-phospholipid syndrome. Age-matched control women were recruited from the community. Left ventricular mass, diastolic function and systolic ejection fraction were assessed with echocardiography; Ea was estimated as 0.9 x (arm-cuff systolic pressure/Doppler stroke volume) and Ees was calculated by the wellvalidated approach of using arm-cuff pressures, Doppler stroke volumes, ejection fraction, pre-ejection and systolic periods [4, 5] . The study was conducted in accordance with the Declaration of Helsinki and approved by the local research ethics committee. Written informed consent was obtained from all participants.
Continuous variables were presented in mean±SD or median [interquartile range] and compared using either the Student t test or Mann-Whitney U test, as appropriate. The mean differences in Ea and Ea/Ees were adjusted for age, systolic ejection fraction and systolic blood pressure. We assessed associations using the Pearson (r) or Spearman (ρ) correlation, as appropriate. All statistical analyses were performed with the SPSS version 19 (SPSS Inc, Chicago, USA). A two-sided P b0.05 was considered statistically significant.
Forty-eight patients with SLE (43±9 years old; disease duration of 14±6 years; 1 [0,2] risk factors) and 20 control women (42±9 years old) were recruited. There were no differences in left ventricular mass, diastolic function and Ees between SLE and control women (PN0.50 for all; Table 1 By design, we had excluded patients with ischemic heart disease and cardiomyopathies, as the role of non-invasive vascular imaging will be of greater relevance in these patients. Therefore, it was not surprising that we did not see any difference in Ees, a marker of ventricular stiffness, between SLE and control women. This was also supported by the similar left ventricular mass and diastolic function between SLE and control women. The small difference in systolic ejection fraction was likely an event of chance and not of important clinical significance. Conversely, Ea was significantly increased in patients with SLE compared to control women despite similar and normal blood pressures. The combination of these changes account for the small magnitude of Ea/Ees effect sizes. The association between Ea, Ea/Ees and adverse events is promising but we acknowledge this is exploratory and will require further validation in larger cohorts with longer follow-up.
In conclusion, arterial elastance and ventricular-arterial coupling are associated with increased cardiovascular risk and are potential novel markers of adverse cardiovascular events in patients with SLE.
Multivessel coronary artery disease (MVD) in ST-segment elevation myocardial infarction (STEMI) is a common clinical condition encountered by interventional cardiologists and it is associated with poorer clinical outcomes than single-vessel disease [1] . Current guidelines recommend culprit-vessel only revascularization (CVR) during primary angioplasty, except in patients that are hemodynamically unstable [2] . Several recent studies have reported promising results from CVR followed by elective second-stage PCI at non-infarct related arteries with significant stenosis. However, there are insufficient data on the long-term outcomes of staged PCI in these patients. We investigated the long-term clinical outcomes of a staged PCI strategy compared to ad hoc PCI and CVR in patients with STEMI and MVD who underwent primary PCI.
We enrolled 575 consecutive patients with STEMI and MVD who visited Chonnam National University Hospital from January 2006 to July 2009. All patients underwent primary PCI within 120 min after being admitted to the hospital. We selected 474 patients after exclusion of patients who presented with cardiogenic shock. Patients were divided into three groups based on the initial interventional strategy: staged PCI (initial index intervention and secondary elective staged PCI during index hospitalization, n = 252); ad hoc (simultaneous infarct-related and non infarct-related artery intervention during the index procedure, n = 67); and culprit-vessel only PCI (CVR, n = 155). The primary endpoint was composite outcome including death from all causes, myocardial infarction (MI) and repeat PCI during 3-year clinical follow-up visits. Repeat PCI included target lesion revascularization, target vessel revascularization and non-target vessel revascularization. Three-year composite outcomes and death from all causes or MI were evaluated using the Kaplan-Meier analysis and compared using a log-rank test. Cox regression analysis was used to identify the clinical impact of staged PCI with complete revascularization (CR) adjusted with clinically relevant covariates. All variables were considered significant when the p-value was b0.05.
There were no significant differences in baseline and angiographic characteristics among groups except for more aged persons (staged vs. ad hoc vs. CVR; 68.8 ± 10.8 vs. 65.5 ± 12.8 vs. 70.7 ± 13.7, p = 0.012), more
